Effects of up to 15 years of recombinant human GH (rh GH) replacement on bone metabolism in adults with Growth Hormone Deficiency (GHD): The Leiden Cohort Study
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Summary: Background: Growth hormone deficiency (GHD) in adulthood may be associated with a decreased bone mineral density (BMD), a decreased bone mineral content (BMC) and an increased fracture risk. Recombinant human GH (rh GH) replacement induces a progressive increase in BMD for up to 5–7 years of treatment. Data on longer follow‐up are, however, scarce. Methods: Two hundred and thirty‐adult GHD patients (mean age 47·1 years, 52·6% female), of whom 88% patients had adult‐onset (AO) GHD, receiving rh GH replacement for ≥5 years were included in the study. Most patients had multiple pituitary hormone deficiencies. Bone turnover markers, BMC and BMD and T‐scores at the lumbar spine and femoral neck were evaluated at baseline, and after 5, 10 and 15 years of rh GH replacement. In addition, clinical fracture incidence was assessed. Results: Mean lumbar spine BMD, lumbar spine BMC and T‐scores gradually increased during the first 10 years of rh GH replacement and remained stable thereafter. Largest effects of rh GH supplementation were found in men. In the small subset of patients using bisphosphonates, use of bisphosphonates did not impact additional beneficial effects in the long term. Low baseline BMD positively affected the change in BMD and BMC over time, but there was a negative effect of high GH dose at 1 year on the change in BMD and BMC over time. Clinical fracture incidence during long‐term rh GH replacement was 20.1/1000 py. Conclusions: Fifteen years of rh GH replacement in GHD adults resulted in a sustained increase in BMD values at the lumbar spine, particularly in men, and stabilization of BMD values at the femoral neck. Clinical fracture incidence was suggested not to be increased during long‐term rh GH replacement.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691
Schuit, S. C. E., van der Klift, M., Weel, A. E. A. M., de Laet, C. E. D. H., Burger, H., Seeman, E., Hofman, A., Uitterlinden, A. G., van Leeuwen, J. P. T. M., & Pols, H. A. P. (2004) · Bone · doi:10.1016/j.bone.2003.10.001 · Cited by 1,651
Molitch, M. E., Clemmons, D. R., Malozowski, S., Merriam, G. R., & Vance, M. L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0179 · Cited by 1,047
Mazziotti, G., Bianchi, A., Bonadonna, S., Nuzzo, M., Cimino, V., Fusco, A., De Marinis, L., & Giustina, A. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060112 · Cited by 141 · cited 2×
“6% in untreated GHD patients (33), suggesting that rhGH supplementation decreases fracture risk in GHD adults.”
BackgroundSkeletal involvement in adult patients with endogenous hypercortisolism
Chiodini, I., Torlontano, M., Carnevale, V., Trischitta, V., & Scillitani, A. (2008) · Journal of Endocrinological Investigation · doi:10.1007/bf03345601 · Cited by 78 · cited 2×
“We have previously shown that 2 years of physiological dose of rhGH in GHD adults increased bone turnover in favor of bone formation, as reflected by a significant increase in BMD (23) that sustained after 7 years of treatment (24).”
BackgroundGötherström, G., Bengtsson, B.-A., Bosæus, I., Johannsson, G., & Svensson, J. (2007) · European Journal of Endocrinology · doi:10.1530/eje.1.02317 · Cited by 76
Drake, W. M., Rodríguez‐Arnao, J., Weaver, J. U., James, I. T., Coyte, D., Spector, T. D., Besser, G. M., & Monson, J. P. (2001) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2001.01246.x · Cited by 76 · cited 2×
“J Clin Endocrinol Metab 1999; 84(11):39563960.”
BackgroundDanilowicz, K., Bruno, O. D., Manavela, M., Gomez, R. M., & Barkan, A. (2008) · Pituitary · doi:10.1007/s11102-008-0126-2 · Cited by 72
Fracture Incidence in GH-Deficient Patients on Complete Hormone Replacement Including GH
Holmer, H., Svensson, J., Rylander, L., Johannsson, G., Rosén, T., Bengtsson, B.-Å., Thorén, M., Höybye, C., Degerblad, M., Bramnert, M., et al. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.070811 · Cited by 66 · cited 1×
“No increased risk was found in AOGHD women and CO-GHD men (32).”
BackgroundBiermasz, N. R., Hamdy, N. A. T., Pereira, A. M., Romijn, J. A., & Roelfsema, F. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02021.x · Cited by 54
Self-citationEffects of 6 years of growth hormone (GH) treatment on bone mineral density in GH‐deficient adults
Clanget, C., Seck, T., Hinke, V., Wüster, C., Ziegler, R., & Pfeilschifter, J. (2001) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2001.01284.x · Cited by 42
Cited by
Yuen, K. C. J., Biller, B. M. K., Radovick, S., Carmichael, J. D., Jasim, S., Pantalone, K. M., & Hoffman, A. R. (2019) · Endocrine Practice · doi:10.4158/gl-2019-0405 · Cited by 298
Mazziotti, G., Frara, S., & Giustina, A. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00005 · Cited by 181
Allo Miguel, G., Serraclara Plá, A., Partida Muñoz, M. L., Martínez Díaz-Guerra, G., & Hawkins, F. (2016) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018816643908 · Cited by 22
Metadata
- Authors
- Appelman‐Dijkstra, N. M., Claessen, K. M. J. A., Hamdy, N. A. T., Pereira, A. M., & Biermasz, N. R.
- Venue
- Clinical Endocrinology
- Publisher
- Wiley
- Published
- 2014-06-05
- Volume
- 81
- Issue
- 5
- Pages
- 727-735
- ISSN
- 0300-0664 (ISSN-L)
- 1365-2265
- OpenAlex
- W2059074655
- Cited by
- 45
- References
- 11
- FWCI
- 1.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.